An international research team has succeeded in deciphering a key mechanism that controls the growth of pancreatic cancers.

A team of researchers at VCU Massey Comprehensive Cancer Center discovered an innovative way to use a drug already approved ...

Pancreatic cancer may evade the immune system using a clever molecular trick. Researchers found that the cancer-driving ...

Pancreatic cancer may evade the immune system not by accident but by actively switching off internal danger signals through ...

MYC‑driven tumors silence innate immune alarms by clearing R‑loop–derived signals, exposing a new therapeutic angle for targeting MYC without broad inhibition.

Novel Treatment Targets in Sarcoma: More Than Just the GIST MYC has proven to be a highly potent oncoprotein when it is overexpressed, but is also a pleiotropic transcription factor essential for ...

Figure 1: INI1 interacts with c-MYC in the two-hybrid system. Figure 2: INI1 directly interacts with c-MYC in vitro. Figure 3: Co-immunoprecipitation of c-MYC with INI1. Figure 4: Dominant-negative ...

The MYC oncogene family plays an important role in neoplastic disease, and has been extensively studied over decades. Evidence showing the N-terminal and C-terminal regions of MYC can function as a ...

MYC family genes are essential for the human organism. According to current knowledge, they regulate the expression of most cellular genes. Misregulation of MYC proteins significantly contributes to ...

MYC targeted therapies offer significant market opportunities, driven by their potential as oncogenic drivers in diverse tumors. The field sees growing R&D on innovative platforms, early-stage ...